Retina | Ophthalmology Innovation Source

Monoclonal Antibody Company XOMA Corp. Shares New Strategy

Monoclonal antibody company Xoma Corp. shared its new strategy of developing an internal pipeline of potential therapeutics. The company’s lead molecule is gevokizumab, a monoclonal antibody directed at the interleukin-1 beta, an important cytokine involved in multiple diseases where inflammation is a key component. Paul Rubin, MD, Senior Vice President, Research and Development and CMO,…

Novaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents

Novaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther. CyclASol and TacroSol compounds, which are ready for Phase II studies, pair with cyclosporine for dry eye and tacrolimus for uveitis, respectively, said Günther. Novaliq also has in development other…

Ocular Therapeutix

Amarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s ReSure Sealant, the first and only FDA approved ophthalmic sealant of its kind, is a synthetic, polyethylene glycol hydrogel used to seal corneal incisions following cataract surgery. The company’s most…

ONL Therapeutics Develops Novel Mechanism To Attack Fas Receptor Apoptosis

ONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role in retinal detachment and AMD, CEO John Freshley reported. The drug targets the pathway activated in Fas-mediated apoptosis, Freshley said. Fas is an antigen encoded to the tumor necrosis factor…

Kala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline

Kala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott reported. Animal investigations showed that LE-MPP retained approximately 10 times the concentration of the agent on the ocular surface at one hour than either lotoprednol etabonate nanoparticle or suspension alone,…

Translatum Medicus Developing Option To Treat Dry AMD

Clinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO Shelley Boyd, MD, FRCSC, explained the company has reverse engineered an animal model to mimic the disease so investigators can test treatments. TMi-018 is a first-in-class transcriptional modulator that is…

Panoptes Developing Inhibitor For Local Treatments In Ocular Disease

Panoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the OIS gathering. Preclinical investigation is focusing on use for intravitreal and oral administration for posterior uveitis, but Panoptes is also researching topical applications for anterior uveitis, dry eye and viral…

pSivida

Paul Ashton talks about the innovation within pSivida and its early stage work on proteins. pSivida has developed 3 of the 4 sustained delivery systems for the vitreous and retina that have been approved either in the US or the EU Presenter: Paul Ashton Dr. Ashton has over 25 years experience in drug delivery. He…

Panoptes Pharma

Franz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology. Presenter: Franz Obermayr, PhD Dr. Franz Obermayr is Co-Founder and serves as CEO of Panoptes. Before that he was Head of Clinical Development at Nabriva, where he led the clinical efforts…

Ocular Therapeutix

Amar Sawhney gives us an update on what’s going on in Ocular Therapeutix, showing us an in depth look at their product pipeline and what we can look forward to. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the…

Clarity Medical Systems

Keith Mullowney presents Clarity’s multi-product business strategy introducing the products: RetCam & HOLOS™. Presenter: Keith Mullowney Keith L. Mullowney joined Clarity in 2005 as the Company’s Chairman of the Board and Chief Executive Officer. Mr. Mullowney has over thirty-five years of medical device industry experience in sales, marketing and general management in both large company…

Neovista – A Challenging Journey

Versant Ventures Managing Director William J. Link PhD talks about the journey of NeoVista through all of its ups and downs. Ultimately Neovista was able to get its CE Mark, but failed to get approved by the FDA due to a spiral of “stacking” risks. Presenter: William J. Link, PhD Bill was Founder, Chairman and…